Selvita S.A. (SLV.WA) is currently considered not halal (non-compliant), per In-house ratio engine (last assessed 2026-08-27). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. SLV.WA files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 49.42% | 30.00% | Fail |
| Interest-bearing investments | 4.94% | 30.00% | Pass |
| Non-permissible income | 0.02% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 40.50% | 33.00% | Fail |
| Interest-bearing investments | 4.05% | 33.00% | Pass |
| Non-liquid assets | 84.61% | at least 20.00% | Pass |
| Non-permissible income | 0.02% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 40.50% | 33.33% | Fail |
| Cash + interest-bearing securities | 4.05% | 33.33% | Pass |
| Accounts receivable | 15.39% | 33.33% | Pass |
| Non-permissible income | 0.02% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 40.50% | 33.33% | Fail |
| Cash + interest-bearing securities | 4.05% | 33.33% | Pass |
| Accounts receivable | 15.39% | 50.00% | Pass |
| Non-permissible income | 0.02% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 33.72% | 33.00% | Fail |
| Cash + interest-bearing securities | 3.37% | 33.00% | Pass |
| Accounts receivable | 9.44% | 33.00% | Pass |
| Non-permissible income | 0.02% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 28.06% | 33.00% | Pass |
| Cash + interest-bearing securities | 2.81% | 49.00% | Pass |
| Accounts receivable | 7.86% | 49.00% | Pass |
| Non-permissible income | 0.02% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 28.06% | 33.33% | Pass |
| Cash + interest-bearing securities | 2.81% | 33.33% | Pass |
| Accounts receivable | 10.66% | 49.00% | Pass |
| Non-permissible income | 0.02% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 44.40 | NEUTRAL |
| Stochastic %K (14) | 35.09 | NEUTRAL |
| CCI (20) | -40.83 | NEUTRAL |
| Williams %R (14) | -64.91 | NEUTRAL |
| MACD (12,26,9) | 0.03 | BUY |
| ROC (10) | 0.19 | BUY |
| Momentum (10) | 0.05 | BUY |
| EMA (10) | 27.11 | SELL |
| SMA (10) | 26.85 | BUY |
| EMA (20) | 27.34 | SELL |
| SMA (20) | 27.52 | SELL |
| EMA (30) | 27.59 | SELL |
| SMA (30) | 27.67 | SELL |
| EMA (50) | 28.22 | SELL |
| SMA (50) | 28.00 | SELL |
| EMA (100) | 30.10 | SELL |
| SMA (100) | 29.86 | SELL |
| EMA (200) | 34.07 | SELL |
| SMA (200) | 35.64 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Diagnostics & Research
Selvita S.A. provides drug discovery, drug development, and contract testing services in Poland. The company offers computer-aided drug design and artificial intelligence solutions, including structure-based drug design, virtual screening, and bioinformatics; medicinal and synthetic, analytical, and solid state chemistry, as well as process chemistry and scale up, and compound management and libraries; structural biology, fragment-based drug discovery, protein production, modification, and characterization; vitro assays and model, mechanistic and target-focused profiling, vitro safety platform, translational research and biomarkers, and specialized discovery platform; vivo models, non-GLP toxicology, histopathology, and tissue biobank; ADME and pharmacokinetic study, bioanalysis, DMPK strategy, and modeling; and proteomic, transcriptomic, spatial mass spectrometry imaging, and data analysis services. It also provides antibody discovery, developability, antibody characterization, antibody engineering, and other modalities. In addition, the company offers active substance, raw materials and drug products comprising scale-up and process chemistry, solid state characterization, CMC analytical support, analytical methods development and validation, nitrozoamines and other impurities, impurities identification, quality control and QP release, stability studies, formulation development, and clinical supply GMP manufacturing; extractables and leachables, and packaging and functionality; bioanalysis of small molecules; and regulatory affairs. Further, it provides method development and validation, physicochemical properties determination, five batch analysis, one batch analysis, impurities identification, certification, stability studies, process chemistry, and solid state characterization services. The company was formerly known as Selvita CRO S.A. and changed its name to Selvita S.A. in October 2019. Selvita S.A. was founded in 2007 and is headquartered in Kraków, Poland.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.